Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.67
OMER's Cash to Debt is ranked higher than
53% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. OMER: 0.67 )
OMER' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 0.67

Equity to Asset -1.05
OMER's Equity to Asset is ranked lower than
51% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OMER: -1.05 )
OMER' s 10-Year Equity to Asset Range
Min: -15.24   Max: 0.7
Current: -1.05

-15.24
0.7
F-Score: 2
Z-Score: -14.41
M-Score: -7.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -12108.90
OMER's Operating margin (%) is ranked higher than
50% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. OMER: -12108.90 )
OMER' s 10-Year Operating margin (%) Range
Min: -3157.25   Max: -605.88
Current: -12108.9

-3157.25
-605.88
Net-margin (%) -10379.73
OMER's Net-margin (%) is ranked higher than
51% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. OMER: -10379.73 )
OMER' s 10-Year Net-margin (%) Range
Min: -2487.25   Max: -630.99
Current: -10379.73

-2487.25
-630.99
ROA (%) -181.59
OMER's ROA (%) is ranked higher than
50% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. OMER: -181.59 )
OMER' s 10-Year ROA (%) Range
Min: -184.63   Max: -50.37
Current: -181.59

-184.63
-50.37
ROC (Joel Greenblatt) (%) -6899.96
OMER's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. OMER: -6899.96 )
OMER' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5343.14   Max: -2071.66
Current: -6899.96

-5343.14
-2071.66
Revenue Growth (3Y)(%) -15.70
OMER's Revenue Growth (3Y)(%) is ranked higher than
70% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. OMER: -15.70 )
OMER' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 7.7
Current: -15.7

0
7.7
EBITDA Growth (3Y)(%) -2.00
OMER's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. OMER: -2.00 )
OMER' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -2
Current: -2

EPS Growth (3Y)(%) 0.50
OMER's EPS Growth (3Y)(%) is ranked higher than
80% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. OMER: 0.50 )
OMER' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 0.5
Current: 0.5

0
0.5
» OMER's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

OMER Guru Trades in Q2 2013

Jim Simons 82,281 sh (-9.62%)
» More
Q3 2013

OMER Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2013

OMER Guru Trades in Q4 2013

Paul Tudor Jones 10,807 sh (New)
» More
Q1 2014

OMER Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OMER

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 1128.00
OMER's P/S is ranked higher than
65% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. OMER: 1128.00 )
OMER' s 10-Year P/S Range
Min: 15.16   Max: 1152.5
Current: 1128

15.16
1152.5
EV-to-EBIT -12.19
OMER's EV-to-EBIT is ranked higher than
55% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OMER: -12.19 )
OMER' s 10-Year EV-to-EBIT Range
Min: -12.4   Max: -2
Current: -12.19

-12.4
-2
Current Ratio 1.62
OMER's Current Ratio is ranked higher than
57% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. OMER: 1.62 )
OMER' s 10-Year Current Ratio Range
Min: 0.41   Max: 6.61
Current: 1.62

0.41
6.61
Quick Ratio 1.62
OMER's Quick Ratio is ranked higher than
59% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. OMER: 1.62 )
OMER' s 10-Year Quick Ratio Range
Min: 0.41   Max: 6.61
Current: 1.62

0.41
6.61

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 29.30
OMER's Price/Median PS Value is ranked higher than
67% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. OMER: 29.30 )
OMER' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 22.6
Current: 29.3

0.48
22.6
Earnings Yield (Greenblatt) -8.20
OMER's Earnings Yield (Greenblatt) is ranked higher than
71% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. OMER: -8.20 )
OMER' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -8.2

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:3O8.Germany,
Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system. Its product OMS302 or Omidria completed its Phase 3 clinical trial is used for lens replacement surgery and is derived from its PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. In November 2013, the FDA conditionally accepted Omidria as the proposed brand name for OMS302 in the U.S. and in December 2013, the EMA accepted Omidria as the proposed brand name for OMS302 in the EU. In addition to Omidria, the Company has other development programs for pain, inflammation, coagulopathies and disorders of the central nervous system. It has six clinical-stage programs in its pipeline; OMS103 for inflammatory pain following arthroscopic partial meniscectomy surgery, which has completed one Phase 3 trial, its PDE10 inhibitor OMS824 for schizophrenia, which is in a Phase 2 clinical program for patients with stable schizophrenia, its PDE10 inhibitor OMS824 for Huntington's disease, which is in Phase 2 clinical program, its MASP-2 antibody OMS721 for the treatment of thrombotic microangiopathies, which has completed dosing in Phase 1 clinical trial and a Phase 2 clinical program is underway, its PPAR? program, in which three Phase 2 clinical trials are being conducted by its collaborators to evaluate a PPAR? agonist, alone or in combination with other agents, for treatment of addiction to opioids and to nicotine and its PharmacoSurgery product OMS201 for use during urological procedures, including uroendoscopic procedures, that has completed a Phase 1/Phase 2 clinical trial in 2010 and is not currently in active clinical trials. As of February 15, 2014, the Company owned or held licenses to a total of 51 issued or allowed patents and 51 pending patent applications in the U.S. and 245 issued or allowed patents and 230 pending patent applications in foreign markets. The Company is subject to regulate under the U.S. and EU governing regulations.
» More Articles for OMER

Headlines

Articles On GuruFocus.com
comment on OMER Mar 06 2013 
Follow Up on a Speculative Options Bet May 27 2011 
Another Two Speculative Options Bets May 13 2011 

More From Other Websites
OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients Nov 19 2014
OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients Nov 19 2014
OMEROS CORP Financials Nov 18 2014
10-Q for Omeros Corp. Nov 12 2014
Omeros (OMER) Catches Eye: Stock Jumps 8.9% Nov 12 2014
Omeros posts 3Q loss Nov 10 2014
Omeros posts 3Q loss Nov 10 2014
Omeros Corp Earnings Call scheduled for 4:30 pm ET today Nov 10 2014
OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 10 2014
Omeros Corporation Reports Third Quarter 2014 Financial Results Nov 10 2014
Q3 2014 Omeros Corp Earnings Release - After Market Close Nov 10 2014
Omeros Announces Positive Data for MASP-2 Inhibitor in Experimental Model of Stroke Nov 06 2014
Omeros Announces Positive Data for MASP-2 Inhibitor in Experimental Model of Stroke Nov 06 2014
Omeros Corporation to Announce Third Quarter 2014 Financial Results on November 10, 2014 Nov 04 2014
Omeros Corporation to Announce Third Quarter 2014 Financial Results on November 10, 2014 Nov 04 2014
Omidria™ Granted Pass-Through Reimbursement Status from CMS Oct 30 2014
Omidria™ Granted Pass-Through Reimbursement Status from CMS Oct 30 2014
Omeros Falls as Enrollment for OMS824 Study is Suspended Oct 23 2014
Omeros (OMER) Crumbles: Stock Tanks by 12.3% Oct 22 2014
Omeros suspends mid-stage trial of Huntington's drug, shares fall Oct 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK